21 completed, 15 recruiting, 7 terminated, 5 unknown. 54 Phase 2, 21 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 54 | Completed 21, Recruiting 15, Terminated 7, Unknown 5, Withdrawn 4, Active not recruiting 2 |
| Phase 1 | 21 | Completed 7, Recruiting 7, Terminated 3, Unknown 2, Withdrawn 2 |
Follow B-cell Lymphoma: new trials by email Literature Review of B-cell Lymphoma trials Research Report on B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-11-03 |
| Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial. bendamustine hydrochloride, Cyclophosphamide, Fludarabine - B-cell Lymphoma | Phase 2 | Recruiting | Swiss Cancer Institute | 92 | 2026-09-24 | 2026-10-27 |
| Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers Pirtobrutinib - Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 2 | Active not recruiting | Eli Lilly and Company | 13 | 2025-08-07 | 2026-04-17 |
| A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma Glofitamab - B-cell Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-06-06 | 2025-09-17 | |
| A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies Tacabrutideg, Sonrotoclax, Zanubrutinib - B-cell Malignancy, Relapsed Cancer | Phase 1 / Phase 2 | Recruiting | BeOne Medicines | 80 | 2024-11-27 | 2026-09-11 |
| A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL ATRA, Pembrolizumab - Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Rita Assi | 24 | 2024-11-18 | 2026-02-10 |
| A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma TQB3702 tablets+Chemotherapy regimen - B-cell Lymphoma | Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 80 | 2024-11-06 | 2024-11-20 |
| CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) CAR20(NAP)-T, Cyclophosphamide, Fludarabine - B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Uppsala University | 18 | 2024-05-01 | 2026-11-10 |
| Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas Zanubrutinib, Rituximab - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 43 | 2024-04-19 | 2026-09-28 |
| An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Magrolimab, Rituximab, CAR T leukapheresis - Large B-cell Lymphoma, B-cell Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2023-09-30 | 2023-11-13 | |
| A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies Anti-CD19 Autologous CAR-T Cell Infusion - B-Cell Leukemia, B-Cell Lymphoma | Phase 1 / Phase 2 | Unknown | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | 60 | 2023-07-01 | 2023-07-11 |
| A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL Mosunetuzumab, Polatuzumab vedotin, Tafasitamab - Hodgkin Lymphoma, B-Cell Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 36 | 2023-04-28 | 2026-09-18 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies CTX112 - B-cell Lymphoma, Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 120 | 2023-03-10 | 2025-11-14 |
| Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma Relmacabtagene Autoleucel, Fludarabine, Cyclophosphamide - B-cell Lymphoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 20 | 2023-01-03 | 2024-01-08 |
| CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine - B-NHL, B-Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 130 | 2022-12-28 | 2026-10-26 |
| Clinical Study of Autologous Stem Cell Transplantation + Anti-CD19 CAR T Cells for B-cell Lymphoma ASCT+CAR-T Cell Infusion - B-cell Lymphoma | Phase 2 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 30 | 2022-12-01 | 2023-03-06 |
| Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies BN301 - B-cell Lymphoma, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | BioNova Pharmaceuticals (Shanghai) LTD. | 9 | 2022-11-25 | 2024-02-21 |
| Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate - B-Cell Lymphoma, Myelodysplastic Syndromes (MDS) | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 80 | 2022-11-01 | 2026-08-07 |
| Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies anti-CD19 UCAR-NK cells - B-cell Lymphoma, B-cell Leukemia | Phase 1 / Phase 2 | Withdrawn | Kunming Hope of Health Hospital | 2022-10-01 | 2022-11-30 | |
| Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma Mosunetuzumab, Lenalidomide - Follicular Lymphoma, Marginal Zone Lymphoma | Phase 2 | Recruiting | Brown University | 52 | 2022-07-14 | 2026-08-20 |
Showing 20 of 54. Sign in to see all of them.
Lymphoma, B-Cell (54) · Lymphoma, Non-Hodgkin (15) · Lymphoma (13) · Lymphoma, Follicular (11) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Lymphoma, B-Cell, Marginal Zone (10) · Burkitt Lymphoma (7) · Hodgkin Disease (7) · Leukemia, B-Cell (7) · Lymphoma, Mantle-Cell (6) · Lymphoma, Large B-Cell, Diffuse (5) · Recurrence (5) · Waldenstrom Macroglobulinemia (5) · Leukemia (3) · Leukemia, Myeloid, Acute (3)
Hemic and Lymphatic Diseases (54) · Immune System Diseases (54) · Immunoproliferative Disorders (54) · Lymphatic Diseases (54) · Lymphoproliferative Disorders (54) · Neoplasms by Histologic Type (54) · Neoplasms (53) · Lymphoma (41) · Lymphoma, Non-Hodgkin (39) · Hematologic Diseases (19) · Leukemia (17) · Leukemia, Lymphoid (17) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Disease Attributes (15)
Rituximab (11) · Cyclophosphamide (9) · fludarabine (8) · Lenalidomide (4) · Mycophenolic Acid (3) · Tacrolimus (3) · Whole-Body Irradiation (3) · fludarabine phosphate (3) · Antilymphocyte Serum (2) · Bortezomib (2) · glofitamab (2) · ibrutinib (2) · obinutuzumab (2) · pirtobrutinib (2) · polatuzumab vedotin (2)
M.D. Anderson Cancer Center (4) · CRISPR Therapeutics AG (2) · Eli Lilly and Company (2) · National Cancer Institute (NCI) (2) · Pharmacyclics LLC. (2) · Uppsala University (2) · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China (1) · Acrotech Biopharma Inc. (1) · BeOne Medicines (1) · Beijing Tongren Hospital (1) · BioNova Pharmaceuticals (Shanghai) LTD. (1) · Brown University (1) · Cancer Research UK (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Dynavax Technologies Corporation (1)
United States (31) · China (11) · France (8) · Australia (7) · Germany (5) · United Kingdom (5) · Sweden (4) · Switzerland (4) · Belgium (3) · Italy (3) · Poland (3) · Brazil (2) · South Korea (2) · Spain (2) · Canada (1)
Abraham Leung, MD (1) · Adam J Olszewski, MD (1) · Andrew Davies, Prof (1) · Annie Weaver, PhD (1) · Baijun Fang, Prof. (1) · Benjamin Kasenda, PD Dr. med. Dr. phil. (1) · Christian Gisselbrecht, MD PHD (1) · Dai Chihara, MD,PHD (1) · David Cunningham (1) · David Marin, MD (1) · Di Yu, PhD (1) · Donald Tsai, MD, PhD (1)
PMID 23295790, PMID 23770158, PMID 26183076, PMID 27964867, PMID 28167659, PMID 33227125, PMID 33676628, PMID 33750072, PMID 34398557, PMID 34780125, PMID 35595730, PMID 37192437, PMID 37407001, PMID 37540566, PMID 37624619, PMID 38861666, PMID 39033770, PMID 39319495, PMID 39415923, PMID 39938019, PMID 40845254, PMID 41055698, PMID 41144785, PMID 41544219, PMID 42069409, PMID 42085626, PMID 42786239
2005 (1), 2015 (1), 2016 (1), 2018 (1), 2019 (1)